肝切除术前门静脉栓塞患者中肌少症与未来肝残端肥大相关性的研究
回顾性分析2012年5月至2023年5月接受门静脉栓塞(PVE)的40例患者,评估肌少症(基于L3骨骼肌指数SMI)与未来肝残端(FLR)肥大的相关性及切除后结局。作者认为PVE前评估肌少症和身体成分可能有助于对FLR生长受损的患者进行分层和治疗。
要点
- PVE后所有患者均出现FLR肥大(P=0.001)。
- SMI与FLR肥大程度、百分比及动力学增长率呈中度正相关。
- PVE前评估肌少症可能有助于分层FLR生长受损患者。
核心结论
- 肌少症(特别是SMI)与PVE后FLR肥大显著相关;PVE前评估肌少症和身体成分可能有助于对FLR生长受损的患者进行分层和治疗。
研究设计与样本
- 回顾性研究,纳入2012年5月至2023年5月接受PVE的患者40例,中位年龄57.5岁(IQR 51-64),男性27/40(67.5%);测量PVE前及PVE后2-4周的总肝体积和FLR体积,计算FLR的肥大程度(DH)、肥大百分比(PH)和动力学增长率(KGR);肌少症采用L3椎体水平的骨骼肌指数(SMI)定义;另评估皮下脂肪指数、内脏脂肪指数(VAI)、腰大肌最大横截面积及L3椎体水平平均肌肉衰减(MA)。
诊断标准与关键数值
- 肌少症采用L3椎体水平的骨骼肌指数(SMI)定义;非肌少症22例,肌少症18例;SMI与DH(r=0.46,P=0.003)、PH(r=0.47,P=0.002)、KGR(r=0.44,P=0.004)呈中度正相关;VAI与DH(r=0.22,P=0.17)、PH(r=0.18,P=0.27)、KGR(r=0.14,P=0.37)呈弱正相关;PVE前FLR与PH(r=-0.35,P=0.03)及KGR(r=-0.12,P=0.47)呈弱负相关。
临床应用与阅片要点
- 作者认为PVE前评估肌少症和身体成分可能有助于对FLR生长受损的患者进行分层和治疗;本研究为印度人群中首个显示SMI与PVE后FLR肥大显著相关的研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To study the correlation between sarcopenia and hypertrophy of the future liver remnant (FLR) in patients undergoing portal vein embolization (PVE) before liver resection, and to assess the outcomes after resection.
METHODS: This retrospective study examined patients underwent PVE from May 2012 to May 2023. Demographic, clinical, and laboratory features were documented and total liver volumes and FLR volumes were measured before and 2-4 weeks after PVE. Degree of hypertrophy (DH), percentage hypertrophy (PH), and kinetic growth rate (KGR) of the FLR were calculated. Sarcopenia was defined using the skeletal muscle index (SMI) at the L3 vertebral level. Subcutaneous adipose index, visceral adipose index (VAI), cross-sectional area of psoas muscle at the largest diameter, and L3 vertebral level mean muscle attenuation (MA) were also assessed.
RESULTS: Forty patients were included in the analysis and the median age was 57.5 (IQR 51-64) and majority were males 27/40(67.5%). Twenty-two patients were non-sarcopenics and 18 were sarcopenics. All patients showed hypertrophy of FLR (P = 0.001). SMI demonstrated moderate positive correlations with DH (r = 0.46, P = 0.003), PH (r = 0.47, P = 0.002), and KGR (r = 0.44, P = 0.004). VAI showed weak positive correlations with DH (r = 0.22, P = 0.17), PH (r = 0.18, P = 0.27), and KGR (r = 0.14, P = 0.37). Pre-PVE FLR demonstrated a weak negative correlation with PH (r = -0.35, P = 0.03) and KGR (r = -0.12, P = 0.47).
CONCLUSIONS: Sarcopenia, specifically SMI, significantly correlates with FLR hypertrophy after PVE. Assessment of sarcopenia and body compartments prior to PVE could help in stratifying and treats patients with impaired FLR growth.
ADVANCES IN KNOWLEDGE: This study with data spanning over 11 years, is the first in the Indian population to demonstrate a significant correlation between SMI, a marker of sarcopenia, and FLR hypertrophy following PVE.
引用
- Baby A, Patidar Y, Mukund A, et al. Correlation between sarcopenia and hypertrophy of the future liver remnant in patients undergoing portal vein embolization before liver resection. Br J Radiol. 2025. PMID: 39799514. doi:10.1093/bjr/tqaf003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。